{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:04Z","timestamp":1792791484196,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017547","name":"Spark Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000848","name":"University of Edinburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"BBSRC","doi-asserted-by":"publisher","award":["BB\/X010945\/1"],"award-info":[{"award-number":["BB\/X010945\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ymthe.2025.07.011","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T23:23:53Z","timestamp":1752794633000},"page":"4799-4819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["AAV-delivered PPT1 provides long-term neurological benefits in CLN1 mice and achieves therapeutic levels in sheep brain"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-1006","authenticated-orcid":false,"given":"Md Suhail","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apeksha","family":"Khatiwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Derby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Rivera-Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Nayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Gentzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen N.","family":"Greenhalgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon G.","family":"Lillico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Gregson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie","family":"Clutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser","family":"Murdoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Wishart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Biferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ramsburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.07.011_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.811686","article-title":"Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview","volume":"13","author":"Simonati","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2025.07.011_bib2","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.bbadis.2013.04.008","article-title":"NCL diseases - clinical perspectives","volume":"1832","author":"Schulz","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2025.07.011_bib3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/376584a0","article-title":"Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis","volume":"376","author":"Vesa","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.07.011_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pediatrneurol.2021.04.002","article-title":"Management of CLN1 Disease: International Clinical Consensus","volume":"120","author":"Augustine","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2025.07.011_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0022-510X(73)90075-0","article-title":"Infantile type of so-called neuronal ceroid-lipofuscinosis. 1. A clinical study of 15 patients","volume":"18","author":"Santavuori","year":"1973","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ymthe.2025.07.011_bib6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/genbio.2021.0013","article-title":"Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases","volume":"1","author":"Puhl","year":"2022","journal-title":"GEN. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.07.011_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.07.011_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(23)00384-8","article-title":"Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study","volume":"23","author":"Schulz","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.07.011_bib9","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of Intraventricular Cerliponase Alfa for CLN2 Disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.07.011_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163107","article-title":"Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep","volume":"132","author":"Nelvagal","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.07.011_bib11","article-title":"Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme","volume":"33","author":"Hahn","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymthe.2025.07.011_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj1445","article-title":"Gene therapy ameliorates bowel dysmotility and enteric neuron degeneration and extends survival in lysosomal storage disorder mouse models","volume":"17","author":"Ziolkowska","year":"2025","journal-title":"Sci. Transl Med."},{"key":"10.1016\/j.ymthe.2025.07.011_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.nbd.2004.03.005","article-title":"Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis","volume":"16","author":"Griffey","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.07.011_bib14","doi-asserted-by":"crossref","first-page":"E5920","DOI":"10.1073\/pnas.1701832114","article-title":"Synergistic effects of treating the spinal cord and brain in CLN1 disease","volume":"114","author":"Shyng","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.07.011_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165772","article-title":"Experimental gene therapies for the NCLs","volume":"1866","author":"Liu","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.ymthe.2025.07.011_bib16","unstructured":"Kotnik, P. (2024). Joint Statement to the Global Batten Disease Community. https:\/\/bdsrafoundation.org\/joint-statement-to-the-global-batten-disease-community-taysha\/."},{"key":"10.1016\/j.ymthe.2025.07.011_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2350\/07-03-0242.1","article-title":"A murine model of infantile neuronal ceroid lipofuscinosis-ultrastructural evaluation of storage in the central nervous system and viscera","volume":"11","author":"Galvin","year":"2008","journal-title":"Pediatr. Dev. Pathol."},{"key":"10.1016\/j.ymthe.2025.07.011_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.nbd.2006.09.001","article-title":"Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis","volume":"25","author":"Kielar","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.07.011_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.expneurol.2009.01.022","article-title":"Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse","volume":"217","author":"Macauley","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.07.011_bib20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.07.011_bib21","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1038\/s41467-021-26744-4","article-title":"Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates","volume":"12","author":"Costa-Verdera","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.07.011_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.07.011_bib23","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.07.011_bib24","unstructured":"NCT06826612. A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease. https:\/\/clinicaltrials.gov\/study\/NCT06826612."},{"key":"10.1016\/j.ymthe.2025.07.011_bib25","doi-asserted-by":"crossref","first-page":"13566","DOI":"10.1073\/pnas.251485198","article-title":"Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice","volume":"98","author":"Gupta","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.07.011_bib26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10545-011-9446-x","article-title":"Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis","volume":"35","author":"Roberts","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2025.07.011_bib27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.21037\/atm.2018.11.39","article-title":"Lysosomal storage disease overview","volume":"6","author":"Sun","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.07.011_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2014.06.009","article-title":"Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease","volume":"70","author":"Dave","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.07.011_bib29","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/nn.3526","article-title":"Neuroprotection and lifespan extension in Ppt1(-\/-) mice by NtBuHA: therapeutic implications for INCL","volume":"16","author":"Sarkar","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2025.07.011_bib30","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.1038\/s41598-019-45859-9","article-title":"CRISPR\/Cas9 mediated generation of an ovine model for infantile neuronal ceroid lipofuscinosis (CLN1 disease)","volume":"9","author":"Eaton","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.07.011_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnen\/62.1.1","article-title":"The neuronal ceroid-lipofuscinoses","volume":"62","author":"Haltia","year":"2003","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2025.07.011_bib32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.nbd.2004.02.010","article-title":"Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis","volume":"16","author":"Bible","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2025.07.011_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1172\/JCI3112","article-title":"Molecular genetics of palmitoyl-protein thioesterase deficiency in the U.S","volume":"102","author":"Das","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.07.011_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hmg\/ddu428","article-title":"The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy","volume":"24","author":"Miller","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.07.011_bib35","article-title":"The Sheep as a Large Animal Model for the Investigation and Treatment of Human Disorders","volume":"11","author":"Banstola","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.ymthe.2025.07.011_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.831838","article-title":"The Translational Benefits of Sheep as Large Animal Models of Human Neurological Disorders","volume":"9","author":"Murray","year":"2022","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.ymthe.2025.07.011_bib37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.tins.2013.01.006","article-title":"Development of cortical folding during evolution and ontogeny","volume":"36","author":"Zilles","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ymthe.2025.07.011_bib38","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jnr.23423","article-title":"Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)","volume":"92","author":"Katz","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ymthe.2025.07.011_bib39","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ymthe.2018.07.015","article-title":"Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease","volume":"26","author":"Mitchell","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.07.011_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1212228","article-title":"Long-term safety and dose escalation of intracerebroventricular CLN5 gene therapy in sheep supports clinical translation for CLN5 Batten disease","volume":"14","author":"Mitchell","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymthe.2025.07.011_bib41","unstructured":"NCT05228145. Gene Therapy Study for Children With CLN5 Batten Disease (CLN5-200). https:\/\/clinicaltrials.gov\/study\/NCT05228145."},{"key":"10.1016\/j.ymthe.2025.07.011_bib42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/hum.2022.163","article-title":"Biodistribution of Adeno-Associated Virus Gene Therapy Following Cerebrospinal Fluid-Directed Administration","volume":"34","author":"Chen","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.07.011_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.51","article-title":"Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna","volume":"1","author":"Hinderer","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.07.011_bib44","unstructured":"Atlas, H.P. (2024). https:\/\/www.proteinatlas.org\/ENSG00000131238-PPT1\/brain."},{"key":"10.1016\/j.ymthe.2025.07.011_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40478-018-0575-4","article-title":"Compromised astrocyte function and survival negatively impact neurons in infantile neuronal ceroid lipofuscinosis","volume":"6","author":"Lange","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.ymthe.2025.07.011_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/biom11040611","article-title":"Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development","volume":"11","author":"Massaro","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2025.07.011_bib47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/nan.12658","article-title":"Spinal manifestations of CLN1 disease start during the early postnatal period","volume":"47","author":"Nelvagal","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.ymthe.2025.07.011_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.961413","article-title":"Mapping sheep to human brain: The need for a sheep brain atlas","volume":"9","author":"Banstola","year":"2022","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.ymthe.2025.07.011_bib49","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.bbadis.2015.05.014","article-title":"Towards a new understanding of NCL pathogenesis","volume":"1852","author":"Cooper","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2025.07.011_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030616","article-title":"Neuropathophysiology of Lysosomal Storage Diseases: Synaptic Dysfunction as a Starting Point for Disease Progression","volume":"9","author":"Para","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymthe.2025.07.011_bib51","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00234-007-0220-6","article-title":"Decreased T2 signal in the thalami may be a sign of lysosomal storage disease","volume":"49","author":"Autti","year":"2007","journal-title":"Neuroradiology"},{"key":"10.1016\/j.ymthe.2025.07.011_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2016.10.022","article-title":"Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration","volume":"67","author":"Cohen-Pfeffer","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2025.07.011_bib53","unstructured":"Neurogene (2024). Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome. https:\/\/ir.neurogene.com\/news-releases\/news-release-details\/neurogene-reports-positive-interim-efficacy-data-first-four-low."},{"key":"10.1016\/j.ymthe.2025.07.011_bib54","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164575","article-title":"Intrathecal AAV9\/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies","volume":"133","author":"Chen","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.07.011_bib55","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/pmic.201400617","article-title":"N-terminome analysis of the human mitochondrial proteome","volume":"15","author":"Vaca Jacome","year":"2015","journal-title":"Proteomics"},{"key":"10.1016\/j.ymthe.2025.07.011_bib56","unstructured":"SignalP-5.0. Signal peptide and cleavage sites in gram+, gram- and eukaryotic amino acid sequences. https:\/\/services.healthtech.dtu.dk\/services\/SignalP-5.0\/."},{"key":"10.1016\/j.ymthe.2025.07.011_bib57","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1073\/pnas.080508097","article-title":"The crystal structure of palmitoyl protein thioesterase 1 and the molecular basis of infantile neuronal ceroid lipofuscinosis","volume":"97","author":"Bellizzi","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.07.011_bib58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/mgme.1999.2809","article-title":"A rapid fluorogenic palmitoyl-protein thioesterase assay: pre- and postnatal diagnosis of INCL","volume":"66","author":"van Diggelen","year":"1999","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.07.011_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells11172641","article-title":"Modelling Neurological Diseases in Large Animals: Criteria for Model Selection and Clinical Assessment","volume":"11","author":"Eaton","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2025.07.011_bib60","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/cne.24079","article-title":"Computation of a high-resolution MRI 3D stereotaxic atlas of the sheep brain","volume":"525","author":"Ella","year":"2017","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.ymthe.2025.07.011_bib61","unstructured":"J.I. Johnson, K.D.S., K.K. Davis, G.M. Kerndt, and B.M. Winn. The Sheep Brain Atlas. https:\/\/brains.anatomy.msu.edu\/brains\/sheep\/index.html."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625005465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625005465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:12Z","timestamp":1792788252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625005465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1525001625005465"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.011","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV-delivered PPT1 provides long-term neurological benefits in CLN1 mice and achieves therapeutic levels in sheep brain","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}